The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study

Henriette Farkas, Ibolya Czaller, Dorottya Csuka, Anikó Vas, Szilvia Valentin, Lilian Varga, Gábor Széplaki, László Jakab, George Füst, Zoltán Prohászka, George Harmat, Beata Visy, István Karádi

Research output: Article

32 Citations (Scopus)

Abstract

Background Danazol is a drug most widely used for the prophylaxis of hereditary angioedema resulting from the deficiency of the C1-inhibitor. Potential hepatotoxic or liver tumor-inducing side effects of long-term danazol prophylaxis have been investigated during the follow-up of hereditary angioedema patients. Methods Characteristic parameters of liver function (including bilirubin, GOT, GPT, γGT, total protein, ALP, LDH), as well as findings of viral serology screens and abdominal ultrasonography-determined during years 0 and 5 of follow-up of patient groups taking/not taking danazol-have been reviewed and analyzed comparatively. Results From a population of 126 hereditary angioedema patients, 46 subjects taking danazol and another 46 not taking danazol fulfilled the inclusion criteria. Longitudinal follow-up did not reveal any clinically relevant difference between the liver function parameters determined in years 0 and 5 in the two groups. Abdominal ultrasound did not detect neoplastic or other potentially treatment-related alterations of the liver parenchyma. There were no discontinuations of treatment during the study. Conclusions Our results clearly suggest that, administered at the lowest effective dose, danazol does not induce liver injury in hereditary angioedema patients.

Original languageEnglish
Pages (from-to)419-426
Number of pages8
JournalEuropean Journal of Clinical Pharmacology
Volume66
Issue number4
DOIs
Publication statusPublished - ápr. 1 2010

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this